BioPharmSignal logoBioPharmSignal

Biotech News

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsEarnings

KPRX (KPRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kprx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-08-19 11:00 EST

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

LENZLenz Therapeutics Inc2026-05-11 20:05 EST

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

EYPTEyePoint Pharmaceuticals2026-05-06 11:00 EST

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

EYPTEyePoint Pharmaceuticals2026-08-05 11:00 EST

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

OTLKOutlook2026-05-15 20:05 EST

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

View all latest news

Kiora Pharmaceuticals

Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in...

Recent company news

KPRXKiora Pharmaceuticals2026-09-08 11:00 EST

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

KPRXKiora Pharmaceuticals2026-08-19 11:00 EST

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-07-02 11:00 EST

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

KPRXKiora Pharmaceuticals2026-06-18 11:00 EST

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Stock data

Close
2.67 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States